Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

Also called NCT06144788

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06144788
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06144788. Randomized; triple masking; primary purpose treatment. Start 2023-11-03 (actual); primary completion 2024-12-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
SGLT2 inhibitor
Lead sponsor
Jeil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06144788
Content hash
76e3c8b5ba8a32179191fa346a3eb06deb72704df8d79d71807e52ab6f68c442